The FDA has cleared Datar Cancer Genetics’ CellDx-Tissue, a genomic profiling assay that analyzes 517 cancer-associated genes from solid tumor tissue to support clinical decision-making, according to the company.
The NCCN now recommends comprehensive molecular profiling for all pancreatic cancer patients eligible for therapy, regardless of stage, to better guide targeted treatment and clinical trial enrollment.
Studies demonstrate spatial transcriptomics, 5-base sequencing, and proteomics applications in oncology diagnostics and therapeutic development.
Astrin Biosciences has earned CAP accreditation for its St. Paul, Minn, lab, supporting the clinical rollout of Certitude Breast, a proteomics-based blood test for early breast cancer detection.
Read More
NeoGenomics has integrated its oncology testing portfolio with Epic Aura, allowing physicians nationwide to order tests and view results within the Epic EHR system, aiming to streamline workflows and expand test adoption, according to the company.
Read More
Circulating tumor DNA testing may help predict metastatic risk in muscle-invasive bladder cancer patients opting for bladder-sparing treatment, according to Fox Chase Cancer Center researchers, though additional biomarkers are needed for local recurrence.
Read More
Foundation Medicine will acquire SAGA Diagnostics’ Pathlight MRD platform, expanding its cancer monitoring portfolio. The $595 million deal is expected to close by Q3 2026, with integration supporting treatment selection and recurrence monitoring.
Read More
City of Hope will evaluate Quest Diagnostics’ Haystack MRD liquid biopsy in a multi-year trial, assessing its use for monitoring breast, colorectal, ovarian, and prostate cancers in about 500 patients across 14 US sites.
Read More
The assay predicts both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Read More
Ultima Genomics presented data at AACR 2026 showing its ppmSeq technology detected circulating tumor DNA at low single-digit parts-per-million in a TRACERx pilot of 50 plasma samples.
Read More
TCM Biotech has received FDA Breakthrough Device Designation for CatCHimera, a liquid biopsy platform for monitoring minimal residual disease in hepatocellular carcinoma using HBV–host genome integration biomarkers.
Read More
Labcorp has launched nationwide testing with Agilent’s FDA-approved PD-L1 IHC 22C3 pharmDx, enabling identification of patients with platinum-resistant ovarian cancer eligible for pembrolizumab immunotherapy.
Read More
A study identified microRNA patterns in blood plasma that could support noninvasive diagnosis and monitoring of the most aggressive form of brain cancer.
Read More
Optical genome mapping detected clinically significant genetic variants missed by standard tests in nearly 20% of acute leukemia cases, according to a 200-patient study.
Read More
AI integrated into molecular profiling workflows identified misclassified lung cancer cases, highlighting its potential role in improving diagnostic accuracy in clinical labs.
Read More
The Idylla CDx MSI Test detects microsatellite instability in colorectal cancer tissue in under three hours, supporting therapy selection for eligible patients.
Read More
CellCarta has secured exclusive global rights to deploy Biofidelity’s Aspyre Lung assay in lung cancer clinical trials, streamlining genomic testing for trial sponsors and reducing reliance on multiple vendors.
Read More
A $4 million financing round will support development of a liquid specimen biorepository and expand biopsy catchment pilot programs at medical institutions across the US.
Read More